Advanced Search
Click Traffic
  • Number of total visits : 3838930
  • Number of visits today : 1288
  • Number of users online :0
  • Number of downloads :1418707
Jian-Jun Li

Jian-Jun Li MD, PhD. Sex: Male; Birthday: 1957,8; Nationality: Chinese; Languages: Chinese, English, and Japanese

Academic and Professional Qualification

MD (Wuhan University, China, 1978-1986)

PhD (Kyushu University, Japan, 1991-1995)

Post-doctoral Fellow (University of Louisville, USA, 1995-1997)

Full-time Appointment

Professor and Associate Chief, Center for Coronary Heart Disease, Fu Wai Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100037, People’s Republic of China

Other Appointments

Vice President, Chinese Molecular College of Cardiology

Member, National Expert Committee on Prevention and Control of Cardiovascular Disease, Expert Member of Chinese Doctor Union

Editorships

Associate Editor-in-Chief: Chinese Journal of Molecular Cardiology, Chinese Circulation Research Journal

Members of Editorial Board of International peer-review Journals: The Open Nitric Oxide Journal (USA), Clinica Chimica Acta (USA), American Journal of Clinical Immunology (USA, Guest Editor),

Chinese Medical Journal (English), World Journal of Cardiology, World Journal of Pharmacology

Members of Editorial Board of Chinese Journals: Chinese Circulation Journal, Chinese arteriosclerosis Journal, Chinese Journal of Geriatric Heart Brain and Vessel Disease, Journal of Clinical Cardiology. Chinese Journal of Cardiovascular disease Research, The World Journal of Cardiology (China)

Reviewer of International peer-reviewed Journals: Heart (British), International Journal of Cardiology (USA), Coronary Artery Disease (USA), Journal of Interventional Cardiology (USA),Acta Pharmalogica Sinica (China), Journal of Cellular Biochemistry (USA), Pharmacological Report (Poland), Clinical Medicine (New Zealand), Vascular Health and Risk Management (USA), Archive of Medical Science (Poland), Mediators of Inflammation (USA), Journal of Clinical Pharmacology (USA), Clinical Cardiology (USA), Cytokine (USA), DNA

and Cellular Biology (USA), Archives of Medical Research (USA), Journal of Clinical Medicine and Research (USA), Cardiovascular Therapeutics (USA), Anatolian Journal of Cardiology (Anatolian), Drug & Aging (USA), Journal of Thrombosis and Thromblysis (USA)                                                                          

Professional Training

Undergraduate: Wuhan University School of Medicine, China

Graduate (MD): Wuhan University School of Medicine, China

Graduate (PhD): Kyushu University School of Medicine, Japan

Postdoctoral fellow (PhD): Louisville University School of Medicine, USA

Primary Cardiology Training: Renmin Hospital, Wuhan University School of Medicine, China

Specialized Cardiology Training: Renmin Hospital, Wuhan University School of Medicine, China

Advanced training in Catheterization and Pacing: Renmin Hospital, Wuhan University School of Medicine, China

Scholarships

Doctor of Medicine (MD): Renmin Hospital, Wuhan University School of Medicine, China

Master Degree of Medicine (MDM): Renmin Hospital, Wuhan University School of Medicine, China

Doctor of Philosophy, Science of Medicine (PhD): Department of Cardiology, Kyushu University School of Medicine, Japan

Scientific Awards

Secondary Awards of National Science and Technology in Advance   2002

Hubei Province Awards of Chinese Science and Technology in Advance

1999, 2000, 2001, 2002, 2003 respectively

Who’s Who in the World-2009, USA

Who’s Who in Medicine and Healthcare-2009, USA

2000 Outstanding Intellectuals of the 21st Century, England

Research activities 

Main research interests: inflammation and atherocslerotic diseases,

and interventional Cardiology specialized in coronary artery disease and Stent

Foundations

Eight foundations have been awarded now by Dr. Jian-Jun Li, MD, PhD. including Hubei Province Natural Scientific Foundation (two projects), Hubei Province Prominent Young Scientific Foundation, National as well as Education Bureau Foundation for Returned Chinese Scholar studied abroad, National Natural Scientific Foundation (three projects), Fu Wai Hospital Grant, Beijing Natural Scientific Foundation, National Project in the Five-year Period Grant, and Specialized Research Fund for the Doctoral Program of Higher Education of China (three projects) awarded by Dr. Jian-Jun Li, MD, PhD.

Career-related data

1978,10~1986,7  Wuhan University School of Medicine, China

1986,7 ~1988,8  Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Resident), China

1988,9~1991, 8  Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Physician in Chief), China

1991,9~1997,11 Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Associate Director Physician), China    

1997,12~2000,2 Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Director Physician, Associate Director ), China    

2000,3~ 2003,7 Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Director Physician, Professor, Associate Director), China     

2001,9~ 2003,7 Department of Cardiology, 1st affiliated Hospital, Wuhan University School of Medicine (Director Physician, Professor, Associate Director, Doctor Advisor), China             

2003, 8~2004,8  Heart Center, 1st affiliated Hospital, Tsinghua University School of Medicine (Director Physician, Professor, Associate Director, Doctor Advisor), China

2004,9-present Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Science, Peking Union Medical College, China    

Study Abroad

1991,10~1992,9  Department of Cardiology, Kyushu University School of Medicine, Japan (Visiting Scholar)

1992,10~1995,11 Department of Cardiology, Kyushu University School of Medicine, Japan (Postgraduate)

1995,10~1996,9 Department of Cardiology, Kyushu University School of Medicine, Japan (Postdoctoral fellow)

1996,9~1997,11 Department of Cardiology, Louisville University School of Medicine, USA (Postdoctoral fellow)

Book Chapters in Chinese

Modern therapy of arrhythmias (1996)

Therapeutics of Hypertension (2000)

Molecular Cardiology (2001)

Diagnostic Approach of Cardiovascular Disease (2002)

Cardiology; Basic Principle of Internal Medicine (2003)

Atherosclerosis: Basics and Clinics (2004)

Internal Medicine (2004)

Hypertension (2004)

Prevention and treatment of Atherosclerosis (2004)

Clinical application of drug-eluting stent (2006)

The manual of Cardiovascular Disease (2006)

Dyslipidmeia (2011)

Book Chapters in English

Li J-J. Chapter 5 The role of inflammation in atherosclerosis. A perspective systemic relationships for the Asian Pacific Region. Edited by Bartold PM, Ishikawa I, Zhang J. 2008;page 12-14.

Keynote presentation in the international meeting

Inflammation and coronary artery disease. The 7th Asian Pacific Society of Periodontology Meeting. 2007, September 12-22, Beijing, China

Prevalence and current practice of vasospastic angina in China. First Asian Summit on coronary spasm 2008 (Annual Scientific Meeting of Japanese Circulation Society), March 28-30, Fukuoka, Japan

Publications in international, peer-reviewed journals indexed by Science Citation Index

1. Ren Y, Zhang M-Z, Chen K-J, You S-J, Li J-J, et al. Clinical epidemiological investigation of TCM syndromes of patients with coronary heart disease. EVID-based Comple Altern Med 2012; In press.

2. Li J-J (correspondence), et al. What is relationship of the effects of aspirin, statins and C-reactive protein? Clin Exp Hypertens 2012; In press.

3. Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, Li J-J. Resveratol in cardiovascular disease: What is known from current research. Heart Fail Rev 2012; In press.

4. Zeng W-J, He J-G, Li J-J (correspondence), et al. Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hypertension. J Clin Pharmacol 2012; In press.

5. Xu H-Y, Li J-J (correspondence), et al. Different impacts of C-reactive protein and lipid profile on atherosclerotic lesions following percutaneous coronary intervention. Coron Artery Dis 2012;Accepted.

6. Nie S-P, Li J-J (correspondence), et al. Anatomic properties of coronary arteries are correlated to corrected TIMI frame count in coronary slow flow phenomenon. Coron Artery Dis 2012; Accapted.

7. Xiong C-M, He J-G, Li J-J (correspondence), et al. Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: A multicenter study. J Clin Pharmacol 2012; 52:425-431.

8. Zhu C-G, Li J-J (correspondence), et al. Myocardial infarction caused by myocardial bridging in an adolescent athlete. J Cardiovasc Med 2012;13:138-140.

9. Li J-J (correspondence), et al. Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: a post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS). Int J Cardiol 2012; 154:365-367.

10. Wen D, Li J-J (correspondence), et al. Elevated plasma levels of interleukin-6, C-reactive protein, tumor necrosis factor-a, matrix metallo- proteinase-9 in patients with aortic dissection. Clin Chim Acta 2012; 413: 198-202.

11. Li J-J, et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. Clin Chim Acta 2012; 413: 139-142.

12. Guo Y-L, Li J-J (correspondence), et al. A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice. Int J Cardiol 2011;153: 211-212.

13. Wen D, Zhou X-L, Li J-J, et al. Role of the plasma C-reactive protein and white blood cell levels in predicting in-hospital clinical events of acute type A aortic dissection. Chin Med J 2011; 124: 2678-2682.

14. LI J-J. Inflammatory rebound phenomenon after abrupt withdrawal of statin is a mature point of view but not hypotheses. Int J Cardiol 2011; 151: 120.

15. Xu B, Dou K-F, Yang Y-J, Chen J-L, Qiao S-B, Wang Y, Li J-J, et al. Comparison of long-term clinical outcome after successful implantation of Firebird and cypher sirolimus-eluting stents in daily clinical practice: analysis of a large single center registry. Chin Med J 2011; 124: 990-996.

16. Li J-J. Inflammation in coronary artery disease. Chin Med J 2011; 124: 3568-3575.

17. Xu Y-L, Li J-J (correspondence), et al. Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting. Chin Med J 2011; 124: 3022-3029.

18. Zeng W-J, Li J-J (correspondence), He J-G, et al. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol 2011; 34: 513-518.

19. Xu Y-L, Li J-J  (correspondence), et al. Role of C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting. Chin Med J 2011; 124: 845-850.

20. Wen D, Zhou X-L, Li J-J  (correspondence), et al. Biomarkers in aortic dissection. Clin Chim Acta 2011; 412: 688-695.

21. Yang Y-J, Kandzari DE, Gao Z, Xue B, Chen J-L, Qiao S-B, Li J-J, et al. Transradial versus transfemoral method of percutaneous transluminal intervention for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. JACC Cardiovasc Interv 2010; 3: 1035-1042.

22. Lu X-L, He J-G, Li J-J (correspondence). Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther 2010; 28: 350-355.

23. Yang P, Li Y, Li J-J (Co-correspondence), et al. Up-regulating PPAR-gamma expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin. Int J Cardiol 2010; 139: 213-217.

24.Gao Z, Xu B, Yang Y, Chen J, Qiao s, Li J-J, et al. Stent thrombosis following drug-eluting stent implantation for coronary burfication lesion: a single center analysis. J Interv Cardiol 2010; 23: 346-351.

25. Liu S-W, Xu B, Chen J, Hu F-H, Wu Y-J, Li J-J, et al. Trend in in-hospital outcome after percutaneous coronary intervention in the drug-eluting stent era. Clin Cardiol 2010; 33: 516.

26. Zheng X, Li J-J (correspondence), Yuan J-Q, et al. Coronary intervention in patients ³ 75 years old with ST-elevation myocardial infarction: in-hospital and 6-month clinical outcome. Chin Med J 2010; 123: 2171-2175.

27. Zhu C-G, Li J-J (correspondence), et al. Gender difference of clinical features in Chinese patients with spontaneous variant angina. Chin Med J 2010; 123: 1377-1381.

28. Li J-J, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from Chinese Coronary Secondary Prevention Study (CCSPS). Ann Med 2010; 42: 231-240.

29. Chen J-L, Gao L-J, Yang Y-J, Li J-J, et al. Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients three-year follow-up results. Chin Med J 2001; 123: 778-782.

30. Dou K-F, Xu B, Yang Y-J, Chen J-L, Qiao S-B, Wang Y, Li J-J, et al. Comparison of long-term clinical outcome after successful implantation of firebird sirolimus- and taxus paclitaxel-eluting stents in Chinese population: analysis of a large single center registry. Chin Med J 2010; 123: 810-815.

31. Li J-J. Is myocardial bridge a bridge connecting to cardiovascular events? Chin Med J 2010; 123: 964-968.

32. Li J-J, et al. Long-term of Xuezhikang on blood pressure in hypertensive patients with myocardial infarction: data from Chinese Coronary Secondary Prevention Study (CCSPS). Clin Exp Hypertens 2010;32:491-498.

33. Li J-J, et al. Impact of C-reactive protein on in-stent restenosis; a meta-analysis. Tex Heart Inst J 2010; 37: 1-9.

34. Li J, Li J-J (correspondence), He J-G, et al. Atorvaststin decreases C-reactive protein–induced inflammatory response in pulmonary artery smooth muscle cell by inhibiting nuclear factor-kB pathway. Cardiovasc Ther 2010; 28:8-14.

35. Yuan J-Q, Li J-J (correspondence), et al. Treatment of mild-moderate calcified coronary lesions with sirolimus-eluting stent: a real world data from a single center. Coron Artery Dis 2010; 21:33-38.

36. Yang Y-J, Qian H-Y, Huang J, Li J-J, et al. Combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells increases benefits in infarcted swine hearts. Arterioscler Thromb Vasc Biol 2009;29: 2076-2082.

37. Gao L-J, Cheng J-L, Chen J, Yang Y-J, Gao R-L, Li J-J, et al.  Long-term clinical efficacy of cutting balloon angiolplasty followed by bare metal stent implantation for treating ostial left anterior descending artery lesions. Clin Cardiol 2009; 32: E31-E35.

38. Song G-Y, Yang Y-J, Wu Y-J, Li J-J, et al. The accelerated post-infarction progression of cardiac remodeling was associated with genetic changes in untreated streptozotocin-induced diabetic rat model. Eur J Heart Fail 2009; 11:911-921.

39. Nan J-L, Li J-J (correspondence). C-reactive protein decreases inter-leukin-8 production in human endothelial progenitor cells by inhibition of p38 MAPK pathway. Chin Med J 2009; 122:1922-1928.

40. Song G-Y, Yang Y-J, Xu B, Li J-J, et al. ST-elevated acute myocardial infarction happening 1 month post stent implantation: late thrombosis in-stent or new lesions? Chin Med J 2009; 122: 1610-1614.

41. Li J-J, et al. Beneficial impact of Xuezhikang in cardiovascular events in elderly hypertensive patients with myocardial infarction from Chinese Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 2009; 49: 947-956.

42. Li J-J, et al. Chronic inflammatory status in patients with coronary artery ectasia. Cytokine 2009: 46: 61-64.

43. Liu H-B, Xu B, Yang Y-J, Wang Y, Qin X-W, Yao M, Yuan J-Q, Chen J, You S-J, Dai J, Ma W-H, Li J-J, et al. Long-term outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database. Chin Med J 2009;122: 681-686.

44. Dou K-F, Xu B, Yang Y-J, Chen J-L, Qiao S-B, Li J-J, et al. Two-year clinical outcomes after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry. Chin Med J 2009; 122: 612-616.

45. Gao Z, Yang Y-J, Xu B, Chen J-L, Qiao S-B, Li J-J, et al. Long-term follow-up of crush versus no crush technique for coronary artery bifurcation lesions. Chin Med J 2009; 122: 627-631.

46. Li J-J, et al. Maximizing benefit of drug-eluting stent by direct coronary stenting because of further reduction of inflammatory response. Chin Med J 2009; 122: 732-735.

47. Li J-J, et al. Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation. Cardiovasc Drugs Ther 2009; 23: 137-143.

48. Luo F, Zhou X-L, Li J-J (Co-correspondence). Inflammatory response associated with aortic dissection. Ageing Res Rev 2009; 8: 31-35.

49. Li J-J, et al. Impact of direct sirolimus-eluting stent implantation on early inflammatory response compared with complementary stenting. Coron Artery Dis 2009; 20: 65-71.

50. Dou K-F, Yang Y-J, Lu R, Qiu H, Yang W-X, Mu Z-W, Gao R-L, Gao Z, Chen J-L, Qian S-B, Li J-J, et al. Clinical and angiographic characteristics of premenopausal women with coronary artery disease. Chin Med J 2008; 121: 2392-2396.

51. Chen J-L, Yang Y-J, Gao L-J, Huang J-H, Qin X-W, Qiao S-B, Xu B, Yao M, Liu H-B, Wu Y-J, Yuan J-Q, Chen J, You S-J, Dai J, Li J-J, et al. Incidence of thrombosis after implantation of drug-eluting stents in patients with coronary artery disease. Chin Med J 2008; 121: 2144-2147.

52. Li J-J, et al. Is systemic inflammation responsible for coronary artery ectasia? Int J Cardiol 2008;130:e69-e70.

53. Chen J, Li J-J (Equal contribution and correspondence), et al. Drug-eluting stents for the treatment of ostial coronary lesions: comparison sirolimus-eluting stent with paclitaxel-eluting stent. Coron Artery Dis 2008;19:507-511.

54. Li J-J, et al. Randomized comparison of early inflammatory response after sirolimus-eluting stent versus bare metal stent implantation in native coronary lesions. Clin Chim Acta 2008;396:38-42.

55. Li J-J. Hypertension control in the very old in China: what we learn from Chinese subgroup characteristics in the Hypertension in the Very Elderly Trial.  Chin Med J 2008;121:1507-1508.

56. Yang Y-J, Kang S, Xu B, Chen J-L, Qiao S-B, Qin X-W, Yao M, Chen J, Wu Y-J, liu H-B, Yuan J-Q, You S-J, Li J-J, et al. Short- and long-term outcomes of single bare metal stent versus drug-eluting stent in nondiabetic patients with simple de novo lesion in the middle and large vessel. J Transl Med 2008;6:42-48.

57. Zhao S-H, Yan C-W, Zhu X-Y, Li J-J (Co-correspondence), et al. Transcatheter occlusion of the rupture sinus of valsalva aneurysm using amplatzer duct occluder. Int J Cardiol 2008;129:81-85.

58. Li J-J, et al. Increased peripheral circulating inflammatory cells and inflammatory markers in patients with variant angina. Coron Artery Dis 2008:19:293-297.

59. Yang Y-J, Qian H-Y, Huang J, Geng Y-J, Gao R-L, Dou K-F, Yang G-S, Li J-J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008;29:1578-1590.

60. Gao Z, Yang Y-J, Cheng J-L, Qian S-B, Yao M, Chen J, Wu Y-J, Liu H-B, Dai J, Yuan J-Q, Li J-J, et al. Is adjunctive balloon postdilatation necessary with drug-eluting stens? One center experience in Chinese patients. Chin Med J 2008;121:513-517.

61. Li J-J. Inflammatory response, drug-eluting stent, and restenosis. Chin Med J 2008;121:566-572.

62. Li J-J, et al. The angiographic prevalence of myocardial bridging in a defined very large Chinese patients with chest pain. Chin Med J 2008; 121:405-408.

63. Gao R-L, Xu B, Chen J-L, Yang Y-J, Qiao S-B, Li J-J, et al. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare metal stent implantation. Am Heart J 2008;155:553-561.

64. Li J-J, et al. Effects of sirolimus-eluting stent on calcified coronary lesions. Chin Med J 2008;121:6-11.

65. Qian H-Y, Yang Y-J, Huang J, Gao R-L, Dou K-F, Yang G-S, Li J-J, et al. Effects of Tongxinluo-faciliated cellular cardiomyoplasty with autologous bone marrow-mesenchymal stem cells on post-infarcted swine hearts. Chin Med J 2007;120:1416-1425.

66. Li J-J, et al. The role of inflammation in coronary artery calcification. Ageing Res Rev 2007;6:263-270.

67. Li J-J, et al. Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine 2007;40:172-176.

68. Li J-J. Inflammation in variant angina: an old topic or a novel finding? Med Hypotheses 2007:69:1155-1156.

69. Li J, Li J-J (correspondence), et al. A rational connection of inflammation with peripheral arterial disease. Med Hypotheses 2007;69:1190-1195.

70. Xu H-X, Li J-J (Correspondence), et al. Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in the vessel: a possible mechanism of anti-atherogenic effects of Losartan. Acta Cardiologica 2007;62:605-611.

71. Yang Y-J, Xu B, Kang S, Pei W-D, Chen J-L, Qin X-W, Qiao S-B, Yao M, Chen J, Wu Y-J, Liu H-B, Yuan J-Q, You S-J, Li J-J, et al. Comparison of in-hospital and long-term outcomes between a cypher stent and a taxus stent in Chinese diabetic patients with coronary artery disease. Chin Med J 2007;120: 1868-1873.

72. Hu W-L, Qiao S-B, Li J-J (correspondence). Decreased C-reactive protein-induced resistin expression in human monocytes by simvastatin. Cytokine 2007;40:201-206.

73. Qian H-Y, Yang Y-J, Huang J, Gao R, Dou K-F, Yang G-S, Li J-J, et al. Intracoronary delivery of autologous bone marrow mononuclear cells readiolabeled by 18F-fluoro-deoxy-glucose: tissue distribution and impact on post-infarct swine hearts. J Cell Biochem 2007;102:64-74.

74.Qian H-Y, Yang Y-J, Li J-J, et al. The role of vascular stem cells in athero- genesis and post-angioplasty restenosis. Ageing Res Rev 2007;6:109-127.

75. Li J-J, et al. Is there delayed restensosis in patients with coronary artery disease treated with sirolimus-eluting stent. Coron Artery Dis 2007;18: 293-298.

76. Li J-J, et al. Drug-eluting stent for the treatment of small coronary lesions: comparison between sirolimus- and paclitaxel-eluting stent. Chin Med J 2007; 120:569-573.

77. Liu H-B, Xu B, Qiao S-B, Yang Y-J, Ma W-H, Qin X-W, Yao M, Wu Y-J, Yuan J-Q, Chen J, You S-J, Dai J, Xia R, Li J-J, et al. A Comparison of clinical and angiographic outcomes after excel bioabsorbable polymer versus firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a “real-world” setting: six-month follow-up results. Chin Med J 2007;120:574-577.

78. Yang Y-J, Xu B, Chen J-L, Kang S, Qiao S-B, Qin X-W, Yao M, Chen J, Wu Y-J, Liu H-B, Yuan J-Q, You S-J, Dai J, Li J-J, et al. Comparison of immediate and follow-up results between transradial and transfemoral approach for percutaneous coronary intervention in true bifurcational lesions. Chin Med J 2007;120:539-544.

79. Li J-J, et al. Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effect. Med Hypotheses 2007;69:1004-1009.

80. Li J-J. Statin therapy may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory basis. Med Hypotheses 2007;69: 333-337.

81. Li J-J. Is any link between inflammation and coronary artery ectasia? Med Hypotheses 2007;69:678-683.

82. Xu Bo, Li J-J (equal contribution and correspondence), et al. Age-based clinical and angiographic outcome after sirolimus-eluting stent implantation in patients with coronary artery disease. Chin Med J 2007;120: 447-451.

83. Li J-J, et al. Elevated plasma C-reactive protein and interleukin-6 levels in patients with slow coronary flow. Clin Chim Acta 2007;385:43-47.

84. Li J-J, et al. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X. Int J Cardiol 2007;122:82-84.

85. Li J-J, et al. Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Clin Chim Acta 2007;376: 163-167.

86. Li J-J, et al. Inflammation in variant angina: is there any evidence? Med Hypotheses 2007;68:635-640.

87. Li J-J, et al. Is the inflammation a contributor for coronary stent restenosis? Med Hypotheses 2007;68:945-951.

88. Qiao S-B, Hou Q, Xu B, Chen J, Liu H-B, Yang Y-J, Wu Y-J, Yuan J-Q, Wu Y, Dai J, You S-J, Zhang P, Gao Z, Dou K-F, Qiu H, Mu C-W, Li J-J, et al. Comparison of drug-eluting stent and bare metal stent in the complex small vessel intervention. Chin Med J 2006;119:596-600.

89. Kang S, Yang Y-J, Xu B, Chen J-L, Qiao S-B, Yao M, Chen J, Wu Y-J, Liu H-B, Dai J, Yuan J-Q, Li J-J, et al. Comparison of drug-eluting stents with bare metal stents in daily practice for bifurcation lesions in Chinese patients. Chin Med J 2006;119:1157-1164.

90. Li J-J, et al. Inflammation in hypertension: primary evidence. Chin Med J 2006;119:1215-1221.

91. Li J-J, et al. Angiographic and clinical outcome for the treatment of in-stent restenosis with sirolimus-eluting stent compared to paclitaxel-eluting stent. Chin Med J 2006;119:1059-1064.

92. Xu B, Li J-J (Correspondence), et al. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han population. Chin Med J 2006;119:533-538.

93. Wang Z-M, Zou Y-B, Song L-B, Zhou X-L, Zhang W, Shen L-D, Wang H, Li J-J, et al. Prevalence of chronic rheumatic heart disease in Chinese adults. Int J Cardiol 2006;107:356-359.

94. Li J-J, et al. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 2006;66:1199-1204.

95. Li J-J, et al. Effects of simvastatin within two weeks on anti-inflammatory cytokine IL-10 in patients with unstable angina Heart 2006;92:529-530.

96. Li J-J, et al. Changes of plasma inflammatory markers after withdrawal of a statin therapy in patients with hyperlipidemia. Clin Chim Acta 2006;366: 269-273.

97. Li J-J. Should slow coronary flow be considered as a coronary syndrome? Med Hypotheses 2006;66:953-956.

98. Li J-J, et al. Is slow coronary flow associated with inflammation? Med Hypotheses 2006;66:504-508.

99. Li J-J, et al. Inflammation: a possible pathogenic link to cardiac syndrome X. Med Hypotheses 2006;66:87-91.

100. Li J-J, et al. Time course of rapid C-reactive protein reduction by prava- statin in patients with stable angina. Angiology 2006;57:1-7.

101. Li J-J. Inflammation: an important mechanism for different clinical entities of coronary artery disease. Chin Med J 2005;118:1817-1826.

102. Li J-J, et al. Effect of 4 weeks of atorvastatin administration on anti- 6

inflammatory cytokine interleukin-10 in patients with unstable angina. Clin Chem 2005;51:1735-1738.

103. Ye P, Li J-J, (Correspondence) et al. Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertri-  (IF:5.579).glyceridemia. Clin Chim Acta 2005;356:229-232.

104.Li J-J, et al. Enhancing anti-inflammatory cytokine IL-10 may be beneficial for acute coronary syndrome. Med Hypotheses 2005;65:103-106.

105. Li J-J, et al. Effects of simvastatin on exercise-induced myocardial ischemia and plasma endothelin-1 levels in patients with stable angina. Clin Chim Acta 2005;354:205-208.

106. Li J-J, et al. Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005;64:925-929.

107. Li J-J, et al. Variant angina in a 17-year-old male. Acta Cardiologica 2005;60:69-71.

108. Li J-J. Should atherosclerosis be considered a cancer of the vascular wall? Med Hypotheses 2005;64:694-698.

109. Wang H-R, Li J-J, (equal contribution and Correspondence), et al. Fluvastatin inhibits the expression of tumor necrosis factor-a and activation of nuclear factor-kB in endothelial cells stimulated by C-reactive protein. Clin Chim Acta 2005;353:53-60.

110. Li J-J, et al. Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina. Clin Chim Acta 2005; 352:217-224.

111. Li J-J, et al. Enhanced response of blood monocytes to C-reactive protein in patients with unstable angina. Clin Chim Acta 2005;352:127-133.

112. Li J-J, et al. Is Hypertension an inflammatory disease? Med Hypotheses 2005;64:236-240.

113. Li J-J, Fang C-H, Jiang H, et al. Time course of inflammatory response after renal artery stenting in patients with atherosclerotic renal artery stenosis. Clin Chim Acta 2004;350:115-121.

114. Fang C-H, Li J-J (Correspondence). Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses 2004;64:192-196.

115. Li J-J. et al. Increased C-reactive protein level after renal stent implantation in patients with atherosclerotic renal stenosis. Angiology 2004;55: 479-484.

116. Xu H-X, Li G-S, Jiang H, Wang J, Lu JJ, Jiang W, Qian HY, Jiang X-J, Li X-Y, Li J-J, et al. Implantation of BM cells transfected with phVEGF enhances functional improvement of the infracted heart. Cytotherapy 2004;6:204-211.

117. Li J-J. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 2004;63:100-102.

118. Wang J-M, Wang Y, Zhu ZS, Zhang MC, Zou Y, Li J-J, et al. Diverse effects of long-term treatment with imidapril and irbersartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats. Life Sci 2004;11:407-420.

119. Wang Y, Wang J-M, Yan S-X, Li M-J, Li J-J, et al. Effects of Angiotensin II receptor-1 antisense oligodoexynucleotides on physiological and pathophysio-logical growth of cardiomyocytes. Acta Pharmacol Sin 2004; 25:561-569.

120. Li J-J, et al. Takayasu’s arteritis accompanied with pericarditis: a case report. Cardiology 2004;102:106-107.

121. Li J-J, et al. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular disease. Med Hypotheses 2004;62:499-506.

122. Li J-J. Silent myocardial ischemia may be related to inflammatory response. Med Hypotheses 2004;62:252-256.

123. Li J-J, et al. Activation of NF-kB and associated with elevated C-reactive protein in patients with unstable angina. Heart Lung & Circ 2004;13:173-178.

124. Li J-J, Cheng M-Z, Cheng X. A pedgree analysis of familial hypercholesterolemia in monozygote twin brothers. Angiology 2003;54: 729-731.

125. Huang C-X, Zhuan Q-Y, Jiang H, Li J-J, et al. Experimental study of the effect of the vagus nerve on atrial electrical remoldeling. J Electrocardiol 2003;36:295-300.

126. Li J-J, et al. Rapid effects on lipid profile and C-reactive protein by simvastatin in patients with hypercholesterolemia. Clin Cardiol 2003;26:472-476.

127. Li J-J, et al. Circadian Variation in myocardial ischemia: possible mechanism involving in this phenomenon. Med Hypotheses 2003;61:240-243.

128. Li J-J, et al. Simvastatin inhibits interleukin-6 release in human cultured monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003;14:329-334.

129. Li J-J, Huang C-X, Jiang H, et al. Ischemic preconditioning detected by treadmill exercise test in patients with stable angina. Angiology 2003;54: 45-50.

130. Li J-J, Li G-S, Huang C-X, et al. Comparative study of catheter-mediated gene transfer into the heart. Chin Med J 2002;114:612-613.

131. Li J-J, Jiang H, Huang C-X, et al. Elevated C-reactive protein of plasma in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology 2002; 53:265-272.

132. Zhao Z-S, Huang C-X, Wang J, Jiang H, Li J-J, et al. Effect of arsenic trioxide on inhibition of restenosis after rabbit vascular injury and its mechanism. Chin Med J 2002;115:1608-1614.

133. Li J-J, Jiang H, Huang C-X, et al. Circadian variation of ischemic threshold in patients with stable angina: relation to plasma endothelin-1. Angiology 2002; 53: 409-414.

134. Li J-JUeno H, Tomita H, et al. Adenovirus-mediated arterial gene transfer dose not require prior injury for submaximal gene expression. Gene Ther 1995;2:351-354.

135. Li J-JUeno H, Yan P, et al. Percutaneous transluminal gene transfer into canine myocardium in vivo by replication-defective adenovirus. Cardiovasc Res 1995;30:97-105.

136. Ueno H, Li J-J, Tomita H, et al. Quantitative analysis of repeat adenovirus-mediated transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol 1995;15:2246-2253.

137. Ueno H, Li J-J, Masuda S, et al. Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo. Arterioscler Thromb Vasc Biol 1997;17:2453- 2460.

138. Ueno H, Yamamoto H, Ito S, Li J-J, Takishita A. Adenovirus-mediated transfer of a dominant negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol 1997;17:898-904.

139. Ueno H, Masuda S, Nishio S, Li J-J, Yamamoto H, Takishita A. Adenovirus-mediated transfer cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. Ann NY Acad Sci 1997;811:401-411.

140. Xue Y-T, Tang X-L, Banerjee S, Takano H, Li RCX, Han H, Qiu Y, Li J-J, Bolli R. Nuclear factor-kB plays an essential role in the late phase of preconditioning in conscious rabbits. Circ Res 1999;84:1095-1109.